Breast tomosynthesis increases cancer detection and reduces recall rates

December 3, 2013

Researchers have found that digital breast tomosynthesis (DBT) led to reduced recall rates and an increase in cancer detection in a large breast cancer screening program. The results of this study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

Digital mammography is the gold standard for , but may yield suspicious findings that turn out not to be cancer. These false-positive findings are associated with a higher recall rate, or the rate at which women are called back for additional imaging or biopsy.

Digital breast tomosynthesis has shown promise at reducing recall rates in all groups of patients, including younger women and women with dense breast tissue. Tomosynthesis is similar to mammography in that it relies on ionizing radiation to generate images of the breast. However, unlike conventional mammography, tomosynthesis allows for three-dimensional (3-D) reconstruction of the breast tissue, which can then be viewed as sequential slices through the breast.

Because DBT technology is relatively new, it is typically used only as a supplemental screening tool, but since October 2011, every patient screened for breast cancer at Hospital of the University of Pennsylvania (HUP) in Philadelphia has been screened using DBT, according to Emily F. Conant, M.D., chief of breast imaging at HUP and the study's lead author.

"We have used DBT on all of our breast screening patients," Dr. Conant said. "Every patient has had it—we have not selected patients because of their risk or density or if they were willing to pay extra. We did not charge extra and were able to provide all of our women with this new technology."

For the study, Dr. Conant and colleagues compared imaging results from 15,633 women who underwent DBT at HUP beginning in 2011 to those of 10,753 patients imaged with digital mammography the prior year. Six radiologists trained in DBT interpretation reviewed the images.

The researchers found that, compared to digital mammography, the average recall rate using DBT decreased from 10.40 percent to 8.78 percent, and the rate increased from 4.28 to 5.25 (per 1,000 patients). The overall positive predictive value—the proportion of positive screening mammograms from which cancer was diagnosed—increased from 4.1 percent to 6.0 percent with DBT.

"Our study showed that we reduced our callback rate and increased our cancer detection rate," Dr. Conant said. "The degree to which these rates were affected varied by radiologist. But importantly, the ratio of callback to cancer detection rate improved significantly for our radiologists."

Dr. Conant notes that tomosynthesis is an evolving platform, and researchers are already seeing a significant improvement in important screening outcomes.

"It's the most exciting improvement to mammography that I have seen in my career, even more important than the conversion from film-screen mammography to ," she said. "The coming years will be very exciting, as we see further improvements in this technology."

Explore further: Tomosynthesis reduces breast cancer screening recall rate

Related Stories

Tomosynthesis reduces breast cancer screening recall rate

July 30, 2013
Digital tomosynthesis is an effective tool for reducing the recall rate in breast cancer screening, according to a new study published online in the journal Radiology.

Digital breast tomosynthesis cuts recall rates by 40 percent

May 3, 2012
Adding digital breast tomosynthesis to 2D mammography screening results in a 40% reduction in patient recall rates compared to routine screening mammography alone, a new study shows.

Novel breast screening technology increases diagnostic accuracy

November 20, 2012
The addition of three-dimensional breast imaging—a technology called tomosynthesis—to standard digital mammography significantly increases radiologists' diagnostic accuracy while reducing false positive recall rates, ...

Tomosynthesis improves detection of infiltrating ductal carcinoma in patients with increased risk

April 13, 2013
Tomosynthesis (3D mammography) is better able to show infiltrating ductal carcinoma than 2D mammography in women at increased risk of breast cancer, a new study shows.

Tomosynthesis ups accuracy of digital mammography

January 4, 2013
(HealthDay)—Using a combination of tomosynthesis, which produces a three-dimensional reconstruction of the breast, with digital mammography increases radiologists' diagnostic accuracy and significantly lowers the number ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.